April 2020 - Cancer Currents Blog
-
Helping Cancer Survivors Cope with Cancer-Related Anxiety and DistressResearchers are exploring ways to support the psychological and emotional needs of cancer survivors and how to tailor existing approaches to meet the needs of specific individuals or groups.
-
Boosting Dendritic Cells Helps the Immune System Find Pancreatic CancerThe number of dendritic cells in a tumor may explain why immunotherapies work for some cancers but not others, a new study suggests. In mice, boosting dendritic cells triggered an immune response that slowed pancreatic tumor growth.
-
NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical TrialsNCI is developing the capability to produce cellular therapies, like CAR T cells, to be tested in cancer clinical trials at multiple hospital sites. Few laboratories and centers have the capability to make CAR T cells, which has limited the ability to test them more broadly.
-
Deaths from Metastatic Melanoma Drop Substantially in the United StatesAfter rising steadily for decades, the number of people in the United States who die each year from the skin cancer melanoma has dramatically dropped in recent years, results from a new study show. Learn what has contributed to the dramatic decline.
-
At NCI, A Robust and Rapid Response to the COVID-19 PandemicNCI is lending its tremendous expertise and unique research capabilities to the global response to the COVID-19 pandemic. NCI Director Dr. Norman Sharpless describes some of the COVID-19 specific research activities NCI has initiated.
-
Selumetinib Approved by FDA to Treat Children with NF1The Food and Drug Administration (FDA) has approved selumetinib (Koselugo) to treat children with neurofibromatosis 1 (NF1), a genetic disorder that causes tumors, called plexiform neurofibromas, to form throughout the nervous system.
-
Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing TypesMore than a decade after vaccination, women who had received a single dose of the HPV vaccine continued to be protected against infection with the two cancer-causing HPV types targeted by the vaccine, an NCI-funded clinical trial shows.
-
Women Experience More Side Effects from Pelvic Radiation than RealizedWomen with cervical or uterine cancer who received radiation to the pelvic region reported side effects much more often using an online reporting system called PRO-CTCAE than they did during conversations with their clinicians, a new study shows.
-
Experimental Drug Prevents Doxorubicin from Harming the HeartAn experimental drug may help prevent the chemotherapy drug doxorubicin from harming the heart and does so without interfering with doxorubicin’s ability to kill cancer cells, according to a study in mice.
-
Training Cancer Researchers: A Conversation with Dr. Oliver BoglerNCI’s Center for Cancer Training (CCT) develops training and career development programs for the next generation of cancer researchers. Here, the new CCT director discusses his goals for CCT and the challenges of training cancer researchers.